Media coverage
2
Media coverage
Title United States : U.S. FDA Approves CARVYKTI (ciltacabtagene autoleucel), Janssens First Cell Therapy, a BCMA-Directed CAR-T Immunotherapy for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma Media name/outlet TendersInfo – News Country/Territory India Date 7/03/22 Persons Sundar Jagannath Title United States : U.S. FDA Approves CARVYKTI (ciltacabtagene autoleucel), Janssens First Cell Therapy, a BCMA-Directed CAR-T Immunotherapy for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma Media name/outlet Mena Report Country/Territory United Kingdom Date 7/03/22 Persons Sundar Jagannath